Abstract
Abstract Our fundamental understanding of the genomic landscape of acute myeloid leukemia (AML) has significantly improved due to large-scale genomic characterization of AML genomes, transcriptomes and methylomes. Retrospective analyses of primary and relapse disease genomes has also illustrated the changes in heterogeneity that occur during progression, and studies of mouse xenografts of AML have illustrated the biological competition among subclones to seed progressive disease. I will discuss next steps in our clinical sequencing of AML, aimed at beginning to apply our fundamental knowledge about the disease to the cancer care setting. Various technical challenges will be highlighted as well as discussing the overall framework for beginning to understand the data we will generate. Citation Format: Elaine R. Mardis. AML genomics: An update. [abstract]. In: Proceedings of the AACR Special Conference on Hematologic Malignancies: Translating Discoveries to Novel Therapies; Sep 20-23, 2014; Philadelphia, PA. Philadelphia (PA): AACR; Clin Cancer Res 2015;21(17 Suppl):Abstract nr IA21.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
